Granules India Limited (GRANULES) AI Stock Analysis

• Market Cap: ₹110.46B
• Dividend Yield: 0.33%
• Average Volume (3M): 39.23K
• Price to Earnings (P/E): 23.0
• Beta (1Y): 1.30
• Revenue Growth: -4.02%
• EPS Growth: -2.61%
• Country: IN
• Employees: 4,057
• Sector: Healthcare
• Sector Strength: 41
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 5.00
• Shares Outstanding: 242,643,720
• 10 Day Avg. Volume: 58,658
• 30 Day Avg. Volume: 39,234
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹511.00
• Price Target Upside: 12.25% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 65 Neutral
• Price Target: ₹511.00 ▲(12.25% Upside)

Granules India Limited shows strong financial performance with solid profitability and cash flow, which is the most significant factor supporting the stock score. Technical indicators reflect a bearish trend, and valuation suggests moderate pricing with a low dividend yield. The absence of recent earnings call data and corporate events means these factors do not influence the score.

Granules India Limited Business Overview & Revenue Model

Company Description

Granules India Limited is a pharmaceutical company headquartered in Hyderabad, India. The company operates in the pharmaceutical sector, focusing on the manufacturing and distribution of active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates (PFIs), and finished dosages. Granules India is known for its large-scale manufacturing capabilities and supplies its products to various markets around the world.

How the Company Makes Money

Granules India Limited generates revenue primarily through the sale of its pharmaceutical products, which include APIs, PFIs, and finished dosages. The company has a robust manufacturing infrastructure that allows for the large-scale production of these products, which are then sold to pharmaceutical companies globally. Granules India also engages in contract manufacturing and supply agreements with multinational pharmaceutical companies, further contributing to its revenue streams. The company's earnings are significantly influenced by its ability to maintain quality standards, manage production costs, and expand its market reach through strategic partnerships and global distribution networks.

Granules India Limited Financial Statement Overview

Summary

Granules India Limited demonstrates a solid financial position with strong profitability and efficient cash generation. While the balance sheet indicates a moderate level of leverage, the company's robust equity and cash flow performance mitigate potential risks. The overall financial health is stable, with room for growth in revenue and further optimization of debt levels.

Income Statement

Granules India Limited shows strong profitability with consistently high gross profit margins. However, revenue growth has seen fluctuations, with a slight decline in the recent year, impacting overall income stability. Net profit margins are solid, indicating efficient cost management.

Balance Sheet

The company maintains a healthy equity base, reflected in a good equity ratio. However, the debt-to-equity ratio is moderately high, indicating reliance on debt financing. Return on equity is strong, showcasing effective use of shareholders' funds for generating profits.

Cash Flow

Granules India Limited exhibits robust operating cash flows, indicating strong cash generation from core operations. Free cash flow has improved significantly, indicating better cash management. The operating cash flow to net income ratio is favorable, highlighting efficient cash utilization.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2022	Mar 2023	Mar 2021
Income Statement
Total Revenue	44.46B	44.82B	45.06B	37.27B	45.12B	31.96B
Gross Profit	22.67B	18.71B	23.76B	17.68B	22.05B	17.41B
EBITDA	9.61B	9.89B	8.26B	7.40B	9.28B	8.82B
Net Income	4.79B	5.02B	4.05B	4.13B	5.17B	5.49B
Balance Sheet
Total Assets	0.00	62.53B	55.21B	45.13B	49.05B	37.13B
Cash, Cash Equivalents and Short-Term Investments	2.17B	5.96B	3.81B	3.96B	3.16B	2.63B
Total Debt	0.00	14.55B	13.15B	11.06B	11.36B	8.49B
Total Liabilities	-34.27B	25.37B	22.95B	19.26B	20.70B	15.40B
Stockholders Equity	34.27B	37.16B	32.26B	25.87B	28.35B	21.73B
Cash Flow
Free Cash Flow	0.00	1.95B	588.38M	-656.53M	4.52B	1.61B
Operating Cash Flow	0.00	7.67B	4.39B	3.32B	6.64B	4.32B
Investing Cash Flow	0.00	-6.95B	-3.60B	-3.80B	-964.52M	-2.77B
Financing Cash Flow	0.00	109.58M	76.64M	1.90B	-5.19B	-2.99B

Granules India Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 455.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GRANULES, the sentiment is Neutral. The current price of 455.25 is below the 20-day moving average (MA) of 466.81, below the 50-day MA of 485.72, and below the 200-day MA of 519.76, indicating a bearish trend. The MACD of -10.57 indicates Positive momentum. The RSI at 46.48 is Neutral, neither overbought nor oversold. The STOCH value of 38.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:GRANULES.

Granules India Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CIPLA	73 Outperform	₹1.23T	22.78		0.85%	6.40%	25.27%
AUROPHARMA	71 Outperform	₹614.49B	18.12		0.38%	7.76%	-2.83%
GRANULES	65 Neutral	₹110.46B	23.02		0.33%	-4.02%	-2.61%
SANOFI	62 Neutral	₹117.33B	32.37		2.30%	-23.93%	-31.53%
GLENMARK	62 Neutral	₹580.50B	55.43		0.12%	9.39%	―
APLLTD	59 Neutral	₹186.09B	30.86		1.16%	8.20%	-4.26%
Sector *	57 Neutral	£5.17B	4.93	-44.55%	2.31%	28.89%	-10.08%

Granules India Limited Corporate Events

Granules India Limited Announces Change in Registered Office Location

Granules India Limited has announced a change in the location of its registered office, moving from Madhapur to Kondapur in Hyderabad, effective April 21, 2025. This strategic relocation could enhance operational efficiency and reflects the company’s ongoing efforts to optimize its business operations, potentially impacting stakeholders positively.